DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

NCT03837873 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma

Interventions

DRUG: Rituximab
DRUG: Etoposide
DRUG: Vincristine
DRUG: Doxorubicin
DRUG: Dexamethasone
DRUG: Cyclophosphamide
DRUG: Lenalidomide
DRUG: Cisplatin
DRUG: Cytarabine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China